Ładuje się......
Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study
BACKGROUND. The ROXANE Italian prospective study evaluated the impact of the 21‐gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. MATERIALS AND METHODS. Nine centers participated. Physicians used the RS test whenever unsure about adjuvant treatm...
Zapisane w:
| Wydane w: | Oncologist |
|---|---|
| Główni autorzy: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
John Wiley & Sons, Inc.
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6853101/ https://ncbi.nlm.nih.gov/pubmed/31152079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0103 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|